The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non–small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
 
Charles Ricordel
Consulting or Advisory Role - AstraZeneca/MedImmune; BMS; Takeda; Takeda
 
Fabrice Barlesi
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Seagen; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
 
Sophie Cousin
No Relationships to Disclose
 
Byoung Chul Cho
Leadership - Interpark Bio; J Ints Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - AstraZeneca; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; Cyrus therapeutics; Guardant Health; J INTS BIO; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Research Funding - Abbvie; AstraZeneca; Bayer; Blueprint medicines; Champions Oncology; Dizal Pharma; Dong-A ST; GI Innovation; Interpark Bio; Janssen; Lilly; Medpacto; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
Other Relationship - DAAN Biotherapeutics
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - START
Stock and Other Ownership Interests - Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Adcendo; Alkermes; Amcure; Amunix; Anaveon; AstraZeneca/MedImmune; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Janssen-Cilag; MedSIR; MonTa Biosciences; MSD Oncology; Nanobiotix; Nouscom; Novartis; OncoDNA; PharmaMar; PsiOxus Therapeutics; Roche/Genentech; Sanofi; Seagen; Servier; Syneos Health; T-Knife; TargImmune Therapeutics
Research Funding - Achilles Therapeutics (Inst); BeiGene; START
Other Relationship - Investigational Therapeutics in Oncological Sciences
 
Tae Min Kim
Consulting or Advisory Role - AstraZeneca/MedImmune; Hanmi; Janssen Oncology; Novartis; Takeda; Yuhan
Speakers' Bureau - Roche/Genentech; Takeda
Research Funding - AstraZeneca
(OPTIONAL) Uncompensated Relationships - AstraZeneca/MedImmune; Bayer; Boryung; Novartis; Roche/Genentech; Sanofi
 
Carole Helissey
Honoraria - Astellas Pharma; AstraZeneca; Janssen; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Janssen; Roche; Sanofi; Viatris
Travel, Accommodations, Expenses - MundiPharma
 
Jin-Soo Kim
Employment - IMBdx
Honoraria - ABION; AstraZeneca; Boehringer Ingelheim; CJ Healthcare; Lilly; Merck
Consulting or Advisory Role - ABION; CJ Healthcare
Research Funding - Alpha Biopharma; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; CJ Healthcare; Hanmi; IL-Yang Pharm; Lilly; Merck; MSD; Novotech; Ono Pharmaceutical; Pfizer; Sanofi; Yuhan
Expert Testimony - CJ Healthcare
 
Maria Vieito
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Roche
 
Valentina Boni
Employment - NEXT Oncology; Quironsalud
Leadership - Next Oncology (Inst)
Honoraria - Amunix; Guidepoint global; IDEAYA Biosciences; Loxo; Puma Biotechnology
Consulting or Advisory Role - Guidepoint Global; OncoArt
Speakers' Bureau - Lilly; Solti; Tactics
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genmab (Inst); Incyte (Inst); Janssen (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Bayer; Start
 
François Ghiringhelli
Honoraria - roche
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Roche/Genentech; Roche/Genentech
 
Mustapha Chadjaa
Employment - Sanofi
 
Nina Masson
No Relationships to Disclose
 
Christine Soufflet
Employment - Excelya
 
Anas Gazzah
No Relationships to Disclose